While both methods have been successfully employed in identifying chemical inhibitor resistant mutations, such as identifying the imatinib-resistant BCR-ABL in chronic myeloid leukemia [1] or the vemurafenib-resistant BRAF mutants in melanoma [4], some limitations still persist. Here, BRAF is linked to melanoma.